Metropolis Healthcare Limited has informed the Exchange regarding a press release dated January 13, 2026, titled "Metropolis Healthcare Limited Launches Centre of Genomics to Scale Precision Diagnostics and Advance Research in India".
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Metropolis Healthcare has launched a dedicated Centre of Genomics to scale precision diagnostics and advance genomic research in India. The centre is backed by two CAP-accredited labs in Delhi NCR and Mumbai, integrating Core Diagnostics' genomics capabilities acquired earlier. It has deployed Illumina's NovaSeq X Series sequencing technology, which can process over 20,000 whole genomes per year. The centre will focus on oncology, reproductive health, neurology, transplant immunology, and rare diseases. Currently offering 220+ validated genomic tests, Metropolis plans to expand its portfolio to over 500 advanced assays within the next 2-3 years.
This expansion positions Metropolis in the high-growth precision medicine space, potentially boosting average revenue per test and opening new revenue streams through pharma partnerships, clinical trials, and companion diagnostics. Positive for long-term growth narrative, though near-term financial impact will depend on adoption and test volumes.